Next Article in Journal
Immune Mechanisms Linking Obesity and Preeclampsia
Next Article in Special Issue
VGLUTs and Glutamate Synthesis—Focus on DRG Neurons and Pain
Previous Article in Journal
Transcriptional Activation of Inflammatory Genes: Mechanistic Insight into Selectivity and Diversity
Previous Article in Special Issue
Computational Studies of Glutamate Transporters
Article Menu

Export Article

Open AccessReview
Biomolecules 2015, 5(4), 3112-3141; doi:10.3390/biom5043112

Overview of Glutamatergic Dysregulation in Central Pathologies

Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Kenneth E. Miller
Received: 5 October 2015 / Revised: 3 November 2015 / Accepted: 5 November 2015 / Published: 11 November 2015
(This article belongs to the Special Issue Role and Regulation of Glutamate Metabolism)
View Full-Text   |   Download PDF [989 KB, uploaded 12 November 2015]   |  

Abstract

As the major excitatory neurotransmitter in the mammalian central nervous system, glutamate plays a key role in many central pathologies, including gliomas, psychiatric, neurodevelopmental, and neurodegenerative disorders. Post-mortem and serological studies have implicated glutamatergic dysregulation in these pathologies, and pharmacological modulation of glutamate receptors and transporters has provided further validation for the involvement of glutamate. Furthermore, efforts from genetic, in vitro, and animal studies are actively elucidating the specific glutamatergic mechanisms that contribute to the aetiology of central pathologies. However, details regarding specific mechanisms remain sparse and progress in effectively modulating glutamate to alleviate symptoms or inhibit disease states has been relatively slow. In this report, we review what is currently known about glutamate signalling in central pathologies. We also discuss glutamate’s mediating role in comorbidities, specifically cancer-induced bone pain and depression. View Full-Text
Keywords: glutamate; glutamate dysregulation; psychiatric disorder; neurodegenerative disease; excitotoxicity glutamate; glutamate dysregulation; psychiatric disorder; neurodegenerative disease; excitotoxicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Miladinovic, T.; Nashed, M.G.; Singh, G. Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules 2015, 5, 3112-3141.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top